Vera Therapeutics, Inc. (VERA) Stock Analysis & Investment Frameworks
Vera Therapeutics, Inc. (VERA) stock analysis on Invetso. Review Vera Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Vera Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Vera Therapeutics, Inc. Key Financial Metrics
- Market Cap: $2.21B
- Revenue: $N/A
- ROE: -84.13%
- ROIC: -85.78%
- Dividend Yield: N/A
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
Vera Therapeutics, Inc. Investment Frameworks
Invetso analyzes Vera Therapeutics, Inc. (VERA) across the following frameworks:
- Vera Therapeutics, Inc. 10Y Growth Potential
- Vera Therapeutics, Inc. Scenario Analysis
- Vera Therapeutics, Inc. Risks & Opportunities
- Vera Therapeutics, Inc. Economic Moat
- Vera Therapeutics, Inc. Business Model
- Vera Therapeutics, Inc. Management
- Vera Therapeutics, Inc. SWOT Analysis
- Vera Therapeutics, Inc. Porter's 5 Forces
- Vera Therapeutics, Inc. PESTLE Analysis
- Vera Therapeutics, Inc. ESG Analysis